Yahoo MoviesDrug dealers surprised by armed police
Two drug dealers were surprised by police as they opened their front door to find armed officers poised to raid their flat in Birmingham
Two drug dealers were surprised by police as they opened their front door to find armed officers poised to raid their flat in Birmingham
The "Global Automotive Event Data Recorder Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
The only real guarantee you'll have in creating your retirement plan is that it won't look like anyone else's. Everyone has a unique set of circumstances that includes both financial and non-financial risks and considerations. While it's important to get the financial piece right, don't forget that one size most definitely does not fit all when it comes to retirement planning. Below, you'll find some of the more popular retirement myths -- and their corresponding realities.
Freedom House notes a steady erosion of democracy under Narendra Modi, amid declining liberty globally.
The European Union should keep borrowing limits for governments suspended in 2022, as it has this year and last, to help the 27-nation bloc's economies return to pre-pandemic levels, the European Commission said on Wednesday. "The general message is that we are keeping a supportive fiscal policy," European Commissioner for Economic and Financial Affairs Paolo Gentiloni told a news conference, adding the EU would, in this way, be in line with the major world economies.
UK chancellor Rishi Sunak promised to do 'whatever it takes' to protect the economy on Wednesday as he delivered his second budget as chancellor.
Rishi Sunak has pledged to do ‘whatever it takes’ to help people and businesses through the coronavirus crisis.
The "Global Gaming Headset Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
Global Ophthalmology Therapeutics Market 2021-2025 The analyst has been monitoring the ophthalmology therapeutics market and it is poised to grow by $ 12. 34 bn during 2021-2025 progressing at a CAGR of 5% during the forecast period.New York, March 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Ophthalmology Therapeutics Market 2021-2025" - https://www.reportlinker.com/p05767743/?utm_source=GNW Our report on ophthalmology therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven increase in prevalence of eye diseases, , and strong uptake of anti-VEGF inhibitors. In addition, increase in prevalence of eye diseases is anticipated to boost the growth of the market as well.The ophthalmology therapeutics market analysis includes product segment and geographical landscapes.The ophthalmology therapeutics market is segmented as below:By Product• Retinal disorder therapeutics• Glaucoma therapeutics• Dry eye disease therapeutics• Eye infections and inflammation therapeutics• Other therapeuticsBy Geographical Landscapes• North America• Europe• Asia• ROWThis study identifies the approval of novel therapeutics and strong drug pipeline as one of the prime reasons driving the ophthalmology therapeutics market growth during the next few years.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on ophthalmology therapeutics market covers the following areas:• Ophthalmology therapeutics market sizing• Ophthalmology therapeutics market forecast• Ophthalmology therapeutics market industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading ophthalmology therapeutics market vendors that include AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the ophthalmology therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.Read the full report: https://www.reportlinker.com/p05767743/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Dublin, March 03, 2021 (GLOBE NEWSWIRE) -- The "OOB Authentication - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 6th edition of this report. The 179-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.Global OOB Authentication Market to Reach US$1.2 Billion by the Year 2027Amid the COVID-19 crisis, the global market for OOB Authentication estimated at US$375.7 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 17.7% over the period 2020-2027. Hardware, one of the segments analyzed in the report, is projected to grow at a 16.9% CAGR to reach US$422.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Phone Based segment is readjusted to a revised 18.3% CAGR for the next 7-year period. This segment currently accounts for a 62.2% share of the global OOB Authentication market.The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 17.1% CAGR for the Period of 2020-2027The OOB Authentication market in the U.S. is estimated at US$111.2 Million in the year 2020. The country currently accounts for a 29.61% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$204.3 Million in the year 2027 trailing a CAGR of 17.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.7% and 15.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR while Rest of European market (as defined in the study) will reach US$204.3 Million by the year 2027. Competitors identified in this market include, among others: CA Technologies, Inc.CensorNet Ltd.Cisco Systems, Inc.Deepnet SecuritySecurEnvoy Ltd.StrikeForce Technologies, Inc.Symantec CorporationTeleSign CorporationtrikeForce Technologies, Inc.VASCO Data Security International, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & REPORT SCOPEII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global RecessionGlobal Competitor Market SharesOOB Authentication Competitor Market Share Scenario Worldwide (in %): 2018E 2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSISIV. COMPETITION Total Companies Profiled: 32 For more information about this report visit https://www.researchandmarkets.com/r/cr8cyd CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Neera Tanden withdraws as Cabinet nominee after facing oppositionRepublican senators, and one Democrat, cited Tanden’s tweets in opposing her nomination for director of the budget office Neera Tanden, Joe Biden’s pick to lead the Office of Management and Budget, has withdrawn her candidacy. Photograph: Reuters
Shares from Asia to Europe gained on Wednesday, as a retreat in U.S. Treasury yields fuelled demand for riskier assets from oil to bitcoin and kept the dollar pinned down. The Euro STOXX 600 added 0.5%, with Frankfurt shares climbing 1% to a record high and London's FTSE gaining 1.1% before the UK's new budget is introduced, with measures to boost the economy.
Biden: US 'on track' to have enough vaccines for all adults by MayPresident says he will direct states to prioritize teachers with a goal of vaccinating all educators by end of March Drive-through vaccinations take place in Detroit’s TCF Center. Photograph: Emily Elconin/Reuters
CALGARY, Alberta (AP) _ Paramount Resources Ltd. (PRMRF) on Wednesday reported fourth-quarter net income of $406 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Calgary, Alberta-based company said it had profit of $3.06. Paramount Resources shares have more than doubled since the beginning of the year.
Figure 1 Location of IP Line and Resistivity, Chargeability and Mag Inversion Sections for Mercedes Target Figure 2 Location of IP Line and Resistivity, Chargeability and Mag Inversion Sections for Cindy Target VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (“Marimaca Copper” or the “Company”)(TSX: MARI) is pleased to announce the results of induced polarization (“IP”) surveys completed at the Mercedes and Cindy Targets (“Mercedes” and “Cindy”) located 3km and 5km to the north of the Company’s flagship Marimaca Copper Project. The surveys have identified extensive high chargeability anomalies, and significant resistivity lows which could represent potential oxide mineralization at each target. Highlights Extensive high chargeability anomalies identified at both Cindy and Mercedes, indicating widespread presence of sulphide mineralizationCoincident with the previously announced magnetic and surface geochemical anomalies at each target Resistivity lows identified may highlight potential for significant oxide mineralization below thin surface cover IP survey results complement the copper geochemical anomalies found at both targets and in combination, will aid drill hole planning for the upcoming exploration campaignResults provide additional information regarding structural controls of mineralization and continue to add to the geological understanding of the Marimaca districtMapping and sampling underway at the Robles Target, located east north east of MarimacaFirst drill rig now onsite and drilling of Marimaca Sulphide Target is in progress. Sergio Rivera, VP Exploration of Marimaca Copper, commented: “As with our flagship Marimaca project, the IP surveys at Mercedes and Cindy highlighted extensive chargeability anomalies, largely coincident with both the magnetic and the broad copper geochemical anomalies previously identified at each target. “Of note are the relatively large, laterally and vertically extensive resistivity lows which occur in the interpreted supergene portion of the systems at Cindy and Mercedes. At Marimaca, the resistivity lows were coincident with the Marimaca Oxide Deposit. Extending this interpretation to Mercedes and Cindy would suggest similar potential for meaningful oxide mineralization. “We are excited by the geological similarities between Marimaca, Cindy and Mercedes – strongly fractured intrusive host rocks; cross cutting dyke swarms and faults; association of magnetite and copper sulphides; similar weathering profiles – and we look forward to drilling them over the coming weeks and months. “We are also conducting mapping and sampling at our new target at Robles and this is shaping up to be another potentially significant oxide target. We hope to delineate drill targets there for testing in the first half of 2021. “Drill rigs are now turning at the Marimaca Sulphide Target and we are also preparing to drill the district targets commencing with Cindy and followed by Mercedes and Robles.” Overview of Induced Polarization Survey and Results Following the success of the IP survey completed over the MOD (refer to release 2 February 2021), the Company completed similar surveys at both the Mercedes and Cindy Targets which are located 3km and 5km to the north of the Company’s flagship Marimaca Copper Project, respectively. As with the previous survey, the objective was to identify potential areas of sulphide mineralization in proximity to the magnetic (refer to release 23 September 2020) and copper geochemical anomalies (refer to releases 9 December 2020 and 17 February 2021) identified through previous exploration work. The IP method was selected because of its deep penetration and high levels of resolution in detecting sulphide mineralization. The surveys were completed by GRS Chile Ltda. and consisted of a single 3.5km east-west line at Mercedes and a second 4.0km east-west line at the Cindy target. Figure 1: Location of IP Line and Resistivity, Chargeability and Mag Inversion Sections for Mercedes Target - https://www.globenewswire.com/NewsRoom/AttachmentNg/4b51e247-f538-4b01-8cf6-92cc9f6409c1 As at Marimaca, the survey highlighted an anomalous resistivity low (darker colours) coincident with the interpreted supergene zone at both Mercedes and Cindy. At Marimaca, these resistivity lows are coincident with the upper, highly fractured, supergene altered, intrusive host rock, containing the supergene oxide copper blanket which makes up the Marimaca Oxide Deposit. The similar resistivity lows at both Mercedes and Cindy appear to be consistent with this interpretation (see Figures 1 and 2). Again, with remarkable similarity to Marimaca, the IP chargeability highs show broad, laterally extensive, blanket like distributions for both targets (see Figures 1 and 2). These anomalies appear to be controlled by the major Naguayán Fault System and have a similar orientation to those at Marimaca. Figure 2: Location of IP Line and Resistivity, Chargeability and Mag Inversion Sections for Cindy Target - https://www.globenewswire.com/NewsRoom/AttachmentNg/1804a1f4-ae47-421a-81a4-4b8e7e7ac12a Qualified Person The technical information in this news release, including the information that relates to geology, drilling and mineralization was prepared under the supervision of, or has been reviewed by Sergio Rivera, Vice President of Exploration, Marimaca Copper Corp, a geologist with more than 36 years of experience and a member of the Colegio de Geólogos de Chile and of the Institute of Mining Engineers of Chile, and who is the Qualified Person for the purposes of NI 43-101 responsible for the design and execution of the drilling program. Mr. Rivera confirms that he has visited the Marimaca Project on numerous occasions, is responsible for the information contained in this news release and consents to its publication. Contact InformationFor further information please visit www.marimaca.com or contact: Tavistock +44 (0) 207 920 3150Jos Simson/Emily Mossmarimaca@tavistock.co.uk Forward Looking Statements This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. These statements relate to future events or the Company’s future performance, business prospects or opportunities. Forward-looking statements include, but are not limited to, the impact of a rebranding of the Company, the future development and exploration potential of the Marimaca Project. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Marimaca Copper, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: risks related to share price and market conditions, the inherent risks involved in the mining, exploration and development of mineral properties, the uncertainties involved in interpreting drilling results and other geological data, fluctuating metal prices, the possibility of project delays or cost overruns or unanticipated excessive operating costs and expenses, uncertainties related to the necessity of financing, the availability of and costs of financing needed in the future as well as those factors disclosed in the Company’s documents filed from time to time with the securities regulators in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador. Accordingly, readers should not place undue reliance on forward-looking statements. Marimaca Copper undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein whether as a result of new information or future events or otherwise, except as may be required by law.
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- ION Geophysical Corporation (NYSE: IO) today announced that the Company has secured more than $20 million in backstop support for its rights offering. This was a critical milestone in the bond restructuring process, as the supporting bondholders had conditioned their participation in the upcoming bond exchange offer on the Company securing this amount of backstop support. The Company will seek to obtain additional backstop support in connection with the rights offering until the maximum amount is secured or the record date (the date on which a person must hold shares to participate) is reached. Oppenheimer & Co. Inc. is serving as the exclusive dealer manager for the rights offering. For additional details regarding the bond exchange offer and rights offering transactions, please refer to the registration statements on Form S-1 and Form S-4 filed with the SEC today. “This milestone was a significant hurdle to closing the bond restructuring transactions,” said Chris Usher, ION’s President and Chief Executive Officer. “The deal provides the opportunity to participate in both debt and equity, depending on the party’s preference, with attractive backstop premiums. We are in the final stretch and remain on track to complete the transactions in early April.” About ION Leveraging innovative technologies, ION delivers powerful data-driven decision-making to offshore energy, ports and defense industries, enabling clients to optimize operations and deliver superior returns. Learn more at iongeo.com. Contacts ION (Investor relations) Executive Vice President and Chief Financial OfficerMike Morrison, +1 281.879.3615 mike.morrison@iongeo.com ION (Media relations) Vice President, CommunicationsRachel White, +1 281.781.1168rachel.white@iongeo.com Registration statements relating to the securities to be offered in the exchange offer and the rights offering in connection with the restructuring transactions have been filed with the Securities and Exchange Commission, but have not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statements become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction. The exchange offer and the rights offering will be made only by means of a prospectus. Copies of each such prospectus, when they become available, will be distributed, as applicable, to our bondholders and shareholders and may also be obtained free of charge at the website maintained by the SEC at or by contacting the appropriate agent for the offerings. Contact information for such agents will be provided when available. The information herein contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include information and other statements that are not of historical fact. Actual results may vary materially from those described in these forward-looking statements. All forward-looking statements reflect numerous assumptions and involve a number of risks and uncertainties. These risks and uncertainties include the risks associated with the timing and development of ION Geophysical Corporation's products and services; pricing pressure; decreased demand; changes in oil prices; agreements made or adhered to by members of OPEC and other oil producing countries to maintain production levels; the COVID-19 pandemic; our ability to complete the Restructuring Transactions and other related matters in a timely manner, if at all; and political, execution, regulatory, and currency risks. For additional information regarding these various risks and uncertainties, see our Form 10-K for the year ended December 31, 2020, filed on February 12, 2021, and our Forms S-1 and S-4, filed on January 29, 2021, and amended on February 12, 2021 and March 3, 2021. Additional risk factors, which could affect actual results, are disclosed by the Company in its filings with the Securities and Exchange Commission ("SEC"), including its Form 10-K, Form 10-Qs and Form 8-Ks filed during the year. The Company expressly disclaims any obligation to revise or update any forward-looking statements.
New research adds to other studies showing that both the Pfizer/BioNTech and Oxford/AstraZeneca jabs have a dramatic effect on severe disease.
Jarkiholi allegedly sexually exploited a woman by assuring her a job in the Karnataka Power Transmission Corporation, and threatened her with consequences if she complained
Britain will give supermarkets and suppliers more time to adapt to post-Brexit trading rules with Northern Ireland, suggesting there would be a new plan to try to minimise disruption that has impeded deliveries of some goods, notably food. After leaving the EU last year, Britain agreed a free trade deal with the bloc to leave its single market and customs union, which came into force at the beginning of this year. But with Northern Ireland, which has a land border with EU member Ireland, having a foot in both camps as part of the UK's customs territory while still aligned with the single market for goods, the new rules have caused disruption.
It also comes in a two-piece set.
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021 LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today reported financial results for the fourth quarter and full year ended December 31, 2020. “In 2020, our Company achieved several important financial and clinical milestones that have positioned us for a productive and busy year ahead. Supported by our recently completed financing, we are beginning the year with a strong cash position, enabling continued growth and expansion of our broad, Microbiome Metabolic Therapies (MMTTM)-based pipeline,” said Dan Menichella, President and Chief Executive Officer of Kaleido. “Recently we reported positive interim results from K031, one of two ongoing non-IND controlled clinical studies of KB109 evaluating outpatients with mild-to-moderate COVID-19 disease. Results demonstrated favorable safety and tolerability as well as evidence of clinical benefit for subjects reporting one or more comorbidities. We look forward to reporting data from both of our KB109 studies in the first quarter of 2021, including the full study population in the K031 study as well as topline results from the K032 study.” Continued Mr. Menichella: “While our immediate priority remains advancing KB109 in COVID-19, we continue to make strong progress across our entire pipeline of novel, targeted, MMT therapies. We are currently enrolling patients in our recently initiated study of KB295 for the treatment of mild-to-moderate ulcerative colitis with topline data targeted for mid-year and continue to advance our Phase 2 clinical trial with KB195 in patients with urea cycle disorder. We are also looking forward to advancing our preclinical programs, particularly in immuno-oncology, cardiometabolic and liver diseases, and around an existing partnership with Janssen to deepen our understanding of how MMTs could potentially play a role in the prevention of childhood-onset atopic and immune conditions.” Recent Program and Corporate Highlights Interim analysis (n=176) from a controlled non-IND clinical study of KB109 in patients with mild-to-moderate COVID-19 demonstrates favorable safety and tolerability, and provides strong signal of clinical benefit for subjects reporting one or more comorbidities In February, Kaleido closed a public offering with gross proceeds of approximately $69.4 million, before deducting underwriting discounts and commissions and other offering expenses Anticipated Near-Term Milestones Topline data from full study population (n=350) from a non-IND clinical study of KB109 in patients with mild-to-moderate COVID-19 as well as results from a second similar study expected in Q1 2021 Topline data from a non-IND clinical study of KB295 in patients with mild-to-moderate ulcerative colitis (UC) expected in mid-2021 Fourth Quarter and Full Year 2020 Financial Results Kaleido reported a net loss of $20.0 million, or $0.56 per common share, for the fourth quarter of 2020 compared to $19.5 million, or $0.65 per common share, for the same period in 2019. For the full year 2020, Kaleido reported a net loss of $81.6 million, or $2.44 per common share, compared to $86.3 million, or $3.36 per common share, for the prior year. The 2020 fourth quarter net loss includes non-cash stock-based compensation expenses of $2.8 million, as compared to $2.2 million in the fourth quarter of 2019. The full year 2020 net loss included non-cash stock-based compensation expenses of $12.7 million, as compared to $10.1 million in 2019. Research and development (R&D) expenses were $14.3 million and $14.1 million for the three months ended December 31, 2020 and 2019, respectively. R&D expenses were $56.0 million and $64.2 million for the year ended December 31, 2020 and 2019, respectively. The full year decrease was primarily due to reduced headcount in our R&D function and less spend with external support for our clinical studies with external CROs and external CMOs and preclinical and clinical development activities. These decreases were partially offset by increased professional and consulting spend related to our studies and increased operating costs related to our facility expansion. General and administrative (G&A) expenses were $5.2 million and $4.9 million for the three months ended December 31, 2020 and 2019, respectively. G&A expenses were $23.9 million and $22.4 million for the year ended December 31, 2020 and 2019, respectively. The full year increase was primarily due to the modification of the vesting provision of stock options and restricted stock units related to the resignation of our former CEO and increased operating costs related to our facility expansion. These increases were partially offset by reduced headcount in our G&A functions. As of December 31, 2020, the Company reported cash and cash equivalents of $46.2 million. Following the close of the February 2021 public offering, the Company has cash runway into the first quarter of 2022. About Microbiome Metabolic Therapies (MMT™)Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates rapidly into clinical studies in healthy subjects and patients. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the Company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., and in Phase 2 or later development. About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of initiation, completion and reporting of results of clinical studies, and our strategy, business plans and focus. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering and those risks more fully discussed in the section entitled "Risk Factors" in Kaleido’s annual report on Form 10-K for the fiscal year ended December 31, 2020, which is available at www.sec.gov, as well as discussions of potential risks, uncertainties, and other important factors in Kaleido’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Kaleido’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Kaleido undertakes no duty to update this information unless required by law. Kaleido Biosciences, Inc. and SubsidiariesCondensed Consolidated Statement of Operations (Unaudited)(in thousands, except share and per share data) Three Months EndedDecember 31, Year EndedDecember 31, 2020 2019 2020 2019 Revenue: Collaboration revenue $243 $— $975 $— Operating expenses: Research and development 14,338 14,087 55,967 64,232 General and administrative 5,205 4,886 23,882 22,428 Total operating expenses 19,543 18,973 79,849 86,660 Loss from Operations (19,300) (18,973) (78,874) (86,660)Other (expense) income (713) (537) (2,746) 329 Net loss $(20,013) $(19,510) $(81,620) $(86,331)Net loss per share—basic and diluted $(0.56) $(0.65) $(2.44) $(3.36)Weighted-average common shares outstanding—basic and diluted 35,981,830 30,091,773 33,450,213 25,703,269 Kaleido Biosciences, Inc. and SubsidiariesCondensed Consolidated Balance Sheet Data (Unaudited)(in thousands) December 31, 2020 December 31, 2019 Assets: Cash and cash equivalents $46,222 $71,241 Other assets 13,122 11,065 Total assets $59,344 $82,306 Liabilities and stockholders' equity Liabilities $38,848 $33,423 Stockholders' equity 20,496 48,883 Total liabilities and stockholders' equity $59,344 $82,306 Contacts: Kaleido Biosciences William Duke, Jr. Chief Financial Officer 617-890-5772william.duke@kaleido.com Investors Mike Biega Solebury Trout 617-221-9660mbiega@soleburytrout.com Media Amy Bonanno Solebury Trout 914-450-0349abonanno@soleburytrout.com